Who
Mike Kelliher
Chief Business Officer
Company insider
Files Form 4 as: Chief Business Officer, Ardelyx; Director, Capricor Therapeutics.
In numbers
- Trades disclosed
- 39
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $385K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 1 Sep 2023
- Last trade
- 21 Aug 2026
- Last filed
- 25 Aug 2026
Companies traded
Activity over time
1 May 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $12K3,104 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $10K2,652 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $7,7222,002 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $12K3,104 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $10K2,652 at $3.86 | filing |
| 21 Aug 2026filed 25 Aug 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $7,7282,002 at $3.86 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $18K2,900 at $6.27 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $12K1,870 at $6.27 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $16K2,478 at $6.27 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $18K2,900 at $6.27 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $12K1,870 at $6.27 | filing |
| 21 May 2026filed 22 May 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $16K2,478 at $6.27 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $49K8,434 at $5.87 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $6,6221,159 at $5.71 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $112 at $5.71 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $50K8,434 at $5.87 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $6,6181,159 at $5.71 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $112 at $5.71 | filing |
| 23 Jan 2026filed 26 Jan 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —103,080 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —154,625 at $0.00 | filing |
News
Pomerantz LLP Issues Important Reminder to Investors in Ardelyx, Inc. ...ARDX · pr-inside.com · 25 Oct 2026Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate BindersARDX · manilatimes.net · 23 Oct 2026November 16, 2026 Deadline: Join Class Action Lawsuit Against Ardelyx, ...ARDX · pr-inside.com · 20 Oct 2026
0 headlines in the last 90 days name Mike Kelliher; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.